{"id":502087,"date":"2020-08-13T13:58:01","date_gmt":"2020-08-13T13:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=502087"},"modified":"2020-08-13T13:58:01","modified_gmt":"2020-08-13T13:58:01","slug":"cutaneous-lupus-erythematosus-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-lupus-erythematosus-epidemiology-forecast-till-2030_502087.html","title":{"rendered":"Cutaneous Lupus Erythematosus Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cutaneous Lupus Erythematosus Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Cutaneous Lupus Erythematosus Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s  &#8220;Cutaneous Lupus Erythematosus Epidemiology Forecast to 2030&#8242; report delivers an in-depth understanding of the disease, historical and forecasted Cutaneous Lupus Erythematosus (CLE) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\">Cutaneous Lupus Erythematosus is a chronic, autoimmune disease affecting the skin, which belongs to the family of lupus erythematosus where the symptoms are restricted to the skin.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-lupus-erythematosus-cle-epidemiology-forecast\" target=\"_blank\">Cutaneous Lupus Erythematosus&nbsp;Epidemiology Insights<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The total prevalent population of Cutaneous Lupus Erythematosus in 7MM in 2017 was 327,569&nbsp;<\/li>\n<li>\n<p>The prevalent cases of Chronic Cutaneous Lupus Erythematosus (CCLE) in the US in 2017 was 92,662<\/p>\n<\/li>\n<li>Cutaneous Lupus Erythematosus cases in the United States in 2017 was 182,765 &nbsp;<\/li>\n<li>The prevalent cases of Cutaneous Lupus Erythematosus in 2017\n<ul>\n<li>UK &#8211; 49,292<\/li>\n<li>Japan &#8211; 22,398<\/li>\n<\/ul>\n<\/li>\n<li>The prevalent cases of Cutaneous Lupus Erythematosus &nbsp;in the US in 2017<\/li>\n<ul>\n<li>71,279- Men<\/li>\n<li>111,487 &#8211; Women<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-lupus-erythematosus-cle-epidemiology-forecast\" target=\"_blank\"><strong>Cutaneous Lupus Erythematosus&nbsp; Epidemiology Segmentation in 7MM from 2017 to 2030<\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li>&nbsp;Total Prevalent Pool of Cutaneous Lupus Erythematosus<\/li>\n<li>Diagnosed Prevalent Pool of Cutaneous Lupus Erythematosus<\/li>\n<li>Gender-Specific Prevalent Pool Of Cutaneous Lupus Erythematosus<\/li>\n<li>Severity-Specific Prevalent Pool Of Cutaneous Lupus Erythematosus<\/li>\n<li>Type-Specific Prevalent Pool of Cutaneous Lupus Erythematosus<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Cutaneous Lupus Erythematosus (CLE) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<\/li>\n<li>The Cutaneous Lupus Erythematosus (CLE) Epidemiology Report and Model provide an overview of the risk factors and global trends of Cutaneous Lupus Erythematosus (CLE) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)<\/li>\n<li>The report provides insight about the historical and forecasted patient pool of Cutaneous Lupus Erythematosus (CLE) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/li>\n<li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population<\/li>\n<li>The report assesses the disease risk and burden and highlights the unmet needs of Cutaneous Lupus Erythematosus (CLE)<\/li>\n<li>The report provides the segmentation of the Cutaneous Lupus Erythematosus (CLE) epidemiology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-lupus-erythematosus-cle-epidemiology-forecast\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-lupus-erythematosus-cle-epidemiology-forecast\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><span>1.&nbsp;Key Insights<\/span>&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>2. Executive Summary of Cutaneous Lupus Erythematosus (CLE)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3.&nbsp;Cutaneous Lupus Erythematosus (CLE): Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.1.&nbsp;Introduction<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.2.&nbsp;Sign and Symptoms<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.3.&nbsp;Pathophysiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.4.&nbsp;Risk Factors<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.5.&nbsp;Diagnosis<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4.&nbsp;Patient Journey<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5.&nbsp;Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.&nbsp;Epidemiology Key Findings<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.2.&nbsp;Assumptions and Rationale: 7MM<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.3.&nbsp;Epidemiology Scenario: 7MM<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.3.1.&nbsp;Cutaneous Lupus Erythematosus (CLE) Epidemiology Scenario in the 7MM (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.4.&nbsp;United States Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.4.1.&nbsp;Cutaneous Lupus Erythematosus (CLE) Epidemiology Scenario in the United States (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.&nbsp;EU-5 Country-wise Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.1. Germany Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.1.1.&nbsp;Cutaneous Lupus Erythematosus (CLE) Epidemiology Scenario in Germany (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.2. France Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.2.1.&nbsp;Cutaneous Lupus Erythematosus (CLE) Epidemiology Scenario in France (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.3. Italy Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.3.1.&nbsp;Cutaneous Lupus Erythematosus (CLE) Epidemiology Scenario in Italy (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.4. Spain Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.4.1.&nbsp;Cutaneous Lupus Erythematosus (CLE) Epidemiology Scenario in Spain (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.5. United Kingdom Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.5.1.&nbsp;Cutaneous Lupus Erythematosus (CLE) Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.6. Japan Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.6.1.&nbsp;Cutaneous Lupus Erythematosus (CLE) Epidemiology Scenario in Japan (2017- 2030)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>6.&nbsp;Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>6.1.&nbsp;Cutaneous Lupus Erythematosus (CLE) Treatment and Management<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>6.2.&nbsp;Cutaneous Lupus Erythematosus (CLE) Treatment Algorithm<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7.&nbsp;KOL Views<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8.&nbsp;Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9.&nbsp;&nbsp;Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.1.&nbsp;Bibliography<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.2.&nbsp;Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10.&nbsp;DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11.&nbsp;Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12.&nbsp;About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cutaneous-lupus-erythematosus-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cutaneous-lupus-erythematosus-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Cutaneous Lupus Erythematosus Epidemiology Forecast to 2030&#8242; report delivers an in-depth understanding of the disease, historical and forecasted Cutaneous Lupus Erythematosus (CLE) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-lupus-erythematosus-epidemiology-forecast-till-2030_502087.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-502087","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/502087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=502087"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/502087\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=502087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=502087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=502087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}